A PET (positron emission tomography) study using 89Zr-Df-IAB2M for glioma

Trial Profile

A PET (positron emission tomography) study using 89Zr-Df-IAB2M for glioma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs IAB 2M (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Feb 2017 Status changed from recruiting to completed.
    • 04 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top